||||||||||Sutent (sunitinib) / Pfizer Trial primary completion date, Metastases: SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma (clinicaltrials.gov) - Jun 12, 2016 P2, N=52, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute N=24 --> 29 | Trial primary completion date: Jun 2012 --> Dec 2016 Trial primary completion date: Mar 2016 --> Jul 2014
||||||||||Sutent (sunitinib) / Pfizer Trial primary completion date, Metastases: SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma (clinicaltrials.gov) - Jan 21, 2016 P2, N=50, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute Trial primary completion date: Mar 2016 --> Jul 2014 Trial primary completion date: Aug 2014 --> Mar 2016
||||||||||Recentin (cediranib) / AstraZeneca Enrollment change, Metastases: AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma (clinicaltrials.gov) - Jun 23, 2015 P2, N=24, Completed, Sponsor: National Cancer Institute (NCI) Trial primary completion date: Aug 2014 --> Mar 2016 N=33 --> 24
||||||||||Sutent (sunitinib) / Pfizer Enrollment closed, Metastases: SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma (clinicaltrials.gov) - Jan 5, 2014 P2, N=50, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute N=72 --> 24 Recruiting --> Active, not recruiting
||||||||||Recentin (cediranib) / AstraZeneca Enrollment change, Metastases: AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma (clinicaltrials.gov) - May 6, 2013 P2, N=33, Completed, Sponsor: National Cancer Institute (NCI) Recruiting --> Active, not recruiting N=24 --> 33
||||||||||Recentin (cediranib) / AstraZeneca Trial completion, Metastases: AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma (clinicaltrials.gov) - May 30, 2012 P2, N=33, Completed, Sponsor: National Cancer Institute (NCI) Recruiting --> Active, not recruiting Active, not recruiting --> Completed